February 03, 2026 07:47 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
After Budget mayhem, bulls return: Sensex, Nifty stage sharp recovery | Dalai Lama wins first Grammy at 90 | Firing outside Rohit Shetty’s Mumbai home: 4 arrested, Bishnoi Gang link emerges | Female suicide attackers emerge at centre of deadly BLA assaults that rocked Pakistan’s Balochistan | Delhi blast: Probe reveals doctors' module planned attacks on global coffee chain | Begging bowl: Pakistan PM says he feels “ashamed” seeking loans abroad | Epstein Files shocker! Zohran Mamdani’s mother Mira Nair mentioned in latest tranche | Bill Gates contracted STD after sex with Russian women? Epstein Files make explosive, unverified claims | Big setback for Modi govt: Supreme Court stays controversial UGC Equity Regulations 2026 amid student protests | ‘Mother of all deals’: PM Modi says India–EU FTA is for 'ambitious India'
Serum Institute of India

Serum Institute seeks financial assistance from govt to boost capacity

| @indiablooms | Apr 08, 2021, at 04:00 am

New Delhi/IBNS: Adar Poonawalla, the CEO of world's largest vaccine manufacturer Serum Institute of India (SII), has told NDTV it needs Rs 3,000 crore in assistance from the Indian government to expand its production capacity which is currently "very stretched" in wake of the export restrictions imposed by the government last month.

Poonawalla stated that the Indian government pays it far less per shot of the vaccine than what is earned in exports, necessitating funding to boost the production capacity.

"This was never budgeted or planned initially, because we were supposed to export and get the funding from export countries but now that that is not happening, we have to find other innovative ways to build our capacity," Poonawalla said.

He admitted that SII is not able to supply the vaccine to every Indian who needs it and at the moment it is prioritising India's needs.

He said the Indian government is paying Rs 150 per shot which is profitable but not enough for reinvesting.

"The price that is set is profitable, however it is not profitable enough to re-invest substantially in building capacity," Poonawalla said.

SII has appealed to the government for financial help after restrictions were imposed on the exports of Covishield to battle a steep rise in cases at home.

Poorer countries as well as some rich nations relied heavily on the Serum Institute of India (SII) to vaccinate their citizens with the AstraZeneca vaccine.

Serum Institute produces over two million doses of Covishield per day at its current capacity.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.